IGM Biosciences (IGMS) News Today $1.36 +0.01 (+0.74%) As of 11:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Price T Rowe Associates Inc. MD Sells 445,260 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS)Price T Rowe Associates Inc. MD lessened its holdings in shares of IGM Biosciences, Inc. (NASDAQ:IGMS - Free Report) by 11.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,568,999 shares of the company's stock after sMay 4 at 4:10 AM | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Stock Price Down 1.5% - Should You Sell?IGM Biosciences (NASDAQ:IGMS) Stock Price Down 1.5% - Here's What HappenedMay 1, 2025 | marketbeat.comBank of America Securities downgrades IGM Biosciences (IGMS) to a SellApril 9, 2025 | markets.businessinsider.comIGM Biosciences, Inc. (NASDAQ:IGMS) Sees Large Decline in Short InterestIGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) was the recipient of a large drop in short interest in March. As of March 15th, there was short interest totalling 928,300 shares, a drop of 19.3% from the February 28th total of 1,150,000 shares. Currently, 5.7% of the shares of the company are short sold. Based on an average daily trading volume, of 448,700 shares, the days-to-cover ratio is presently 2.1 days.April 1, 2025 | marketbeat.comIGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Rating of "Reduce" from AnalystsShares of IGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) have been assigned an average rating of "Reduce" from the ten ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and nine have assigned a hold ratingMarch 25, 2025 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Shares Up 5.9% - Here's WhyIGM Biosciences (NASDAQ:IGMS) Shares Up 5.9% - What's Next?March 25, 2025 | marketbeat.comIGM Biosciences (IGMS) Gets a Hold from RBC CapitalMarch 7, 2025 | markets.businessinsider.comMorgan Stanley Sticks to Their Sell Rating for IGM Biosciences (IGMS)March 7, 2025 | markets.businessinsider.comIGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Rating of "Reduce" from BrokeragesIGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) has been given an average recommendation of "Reduce" by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and nine have assignedFebruary 28, 2025 | marketbeat.comIGM Biosciences (IGMS) Projected to Post Quarterly Earnings on ThursdayIGM Biosciences (NASDAQ:IGMS) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comIgm BiosciencesFebruary 16, 2025 | forbes.comIGM Biosciences (IGMS) Receives a Hold from Bank of America SecuritiesFebruary 13, 2025 | markets.businessinsider.comIGM Biosciences stock plunges to 52-week low of $1.59January 28, 2025 | msn.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMSJanuary 28, 2025 | prnewswire.comIgm biosciences principal accounting officer sells $1,907 in stockJanuary 17, 2025 | msn.comBank of America Securities Sticks to Their Hold Rating for IGM Biosciences (IGMS)January 13, 2025 | markets.businessinsider.comJPMorgan Chase & Co. Upgrades IGM Biosciences (NASDAQ:IGMS) to NeutralJPMorgan Chase & Co. upgraded IGM Biosciences from an "underweight" rating to a "neutral" rating in a research note on Monday.January 13, 2025 | marketbeat.comIGM Biosciences downgraded to Hold from Buy at JefferiesJanuary 11, 2025 | finance.yahoo.comIGM Biosciences upgraded to Neutral from Underweight at JPMorganJanuary 11, 2025 | markets.businessinsider.comStifel Downgrades IGM Biosciences (IGMS)January 11, 2025 | msn.comJefferies downgrades IGM Biosciences (IGMS) to a HoldJanuary 10, 2025 | markets.businessinsider.comIGM Biosciences Stock: Bad News With No Turnaround In SightJanuary 10, 2025 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: IGM Biosciences (IGMS) and Abivax SA Sponsored ADR (ABVX)January 10, 2025 | markets.businessinsider.comIGM Biosciences to cut 73% of workforce as latest pivot fails to pan out, sending stock down 69%January 10, 2025 | msn.comIGM Bio plunges as Wall Street downgrades on portfolio shakeupJanuary 10, 2025 | msn.comJefferies Financial Group Reiterates "Hold" Rating for IGM Biosciences (NASDAQ:IGMS)Jefferies Financial Group restated a "hold" rating and issued a $2.00 target price (down from $48.00) on shares of IGM Biosciences in a research note on Friday.January 10, 2025 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Price Target Cut to $2.00 by Analysts at Truist FinancialTruist Financial lowered their target price on shares of IGM Biosciences from $12.00 to $2.00 and set a "hold" rating on the stock in a research note on Friday.January 10, 2025 | marketbeat.comIGM Biosciences' (IGMS) Neutral Rating Reaffirmed at WedbushWedbush restated a "neutral" rating and set a $3.00 price objective (down from $22.00) on shares of IGM Biosciences in a research report on Friday.January 10, 2025 | marketbeat.comIGM Biosciences halts development of auto-immune treatments, shares plummetJanuary 10, 2025 | au.investing.comAMD downgraded, Nike upgraded: Wall Street's top analyst callsJanuary 10, 2025 | finance.yahoo.comIGM Biosciences downgraded to Market Perform from Outperform at BMO CapitalJanuary 10, 2025 | markets.businessinsider.comIGM Biosciences (IGMS) was downgraded to a Sell Rating at Morgan StanleyJanuary 10, 2025 | markets.businessinsider.comIGM Biosciences (NASDAQ:IGMS) Downgraded to Underweight Rating by Morgan StanleyMorgan Stanley cut shares of IGM Biosciences from an "equal weight" rating to an "underweight" rating and lowered their price objective for the company from $12.00 to $2.00 in a research report on Friday.January 10, 2025 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Rating Lowered to "Hold" at Stifel NicolausStifel Nicolaus lowered IGM Biosciences from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $27.00 to $2.50 in a research report on Friday.January 10, 2025 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Downgraded by Royal Bank of Canada to Sector PerformRoyal Bank of Canada lowered IGM Biosciences from an "outperform" rating to a "sector perform" rating and lowered their target price for the company from $20.00 to $1.50 in a research note on Friday.January 10, 2025 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Downgraded by Guggenheim to "Neutral"Guggenheim cut shares of IGM Biosciences from a "buy" rating to a "neutral" rating in a research note on Friday.January 10, 2025 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Given "Market Perform" Rating at BMO Capital MarketsBMO Capital Markets restated a "market perform" rating and set a $2.00 price target (down from $21.00) on shares of IGM Biosciences in a research report on Friday.January 10, 2025 | marketbeat.comIGM Biosciences to Halt Development of Imvotamab, Cut 73% of StaffJanuary 9, 2025 | marketwatch.comIGM Biosciences cuts workforce, halts a couple of product developmentsJanuary 9, 2025 | msn.comIGM to slash 73% of workforce, halt two drug programsJanuary 9, 2025 | msn.comIGM Biosciences Provides Strategic Update on Autoimmunity Pipeline ProgramsJanuary 9, 2025 | globenewswire.comIGM Biosciences, Inc. (NASDAQ:IGMS) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of IGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) have been given an average rating of "Moderate Buy" by the eight brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy ratJanuary 9, 2025 | marketbeat.comIgm biosciences principal accounting officer sells shares for $4,031December 20, 2024 | investing.comMary Beth Harler Sells 1,708 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) StockDecember 19, 2024 | insidertrades.comIGM Biosciences, Inc. (NASDAQ:IGMS) CEO Mary Beth Harler Sells 1,708 SharesIGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) CEO Mary Beth Harler sold 1,708 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $7.48, for a total value of $12,775.84. Following the sale, the chief executive officer now owns 347,032 shares of the company's stock, valued at approximately $2,595,799.36. This represents a 0.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.December 18, 2024 | marketbeat.comIGM Biosciences, Inc. (NASDAQ:IGMS) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of IGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold rDecember 15, 2024 | marketbeat.comIGM Biosciences initiated with an Outperform at BMO CapitalDecember 6, 2024 | markets.businessinsider.comBMO Capital Initiates Coverage of IGM Biosciences (IGMS) with Outperform RecommendationDecember 6, 2024 | msn.comIGM Biosciences (NASDAQ:IGMS) Shares Gap Up - Here's What HappenedIGM Biosciences (NASDAQ:IGMS) Shares Gap Up - Here's What HappenedDecember 6, 2024 | marketbeat.comBMO Capital Markets Begins Coverage on IGM Biosciences (NASDAQ:IGMS)BMO Capital Markets began coverage on IGM Biosciences in a research report on Friday. They issued an "outperform" rating and a $21.00 target price on the stock.December 6, 2024 | marketbeat.com Get IGM Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter. Email Address IGMS Media Mentions By Week IGMS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IGMS News Sentiment▼0.880.73▲Average Medical News Sentiment IGMS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IGMS Articles This Week▼23▲IGMS Articles Average Week Get IGM Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GLUE News PROK News ATAI News ATYR News PHAT News CYRX News ATXS News AQST News AURA News PVLA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IGMS) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGM Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IGMS Stock Free IGMS Stock Alerts